Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Organogenesis Holdings (ORGO) Long-Term Debt Repayments (2018 - 2019)

Organogenesis Holdings has reported Long-Term Debt Repayments over the past 2 years, most recently at $31.5 million for Q4 2019.

For Q4 2019, Long-Term Debt Repayments changed N/A year-over-year to $31.5 million; the TTM value through Dec 2021 reached $31.5 million, changed 0.0%, while the annual FY2021 figure was -$60.0 million, 700.0% down from the prior year.
Long-Term Debt Repayments for Q4 2019 was $31.5 million at Organogenesis Holdings, up from $17.6 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $31.5 million in Q4 2019 and troughed at $10000.0 in Q1 2018.